Compare AAUC & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAUC | AMRX |
|---|---|---|
| Founded | N/A | 2002 |
| Country | Canada | United States |
| Employees | 2252 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | N/A | 2018 |
| Metric | AAUC | AMRX |
|---|---|---|
| Price | $31.85 | $13.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 257.3K | ★ 1.3M |
| Earning Date | 03-31-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | $63.46 | $4.48 |
| Revenue Next Year | $25.91 | $7.13 |
| P/E Ratio | ★ N/A | $59.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $7.02 |
| 52 Week High | $32.08 | $15.42 |
| Indicator | AAUC | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 55.99 |
| Support Level | $30.99 | $12.50 |
| Resistance Level | $32.08 | $13.54 |
| Average True Range (ATR) | 0.24 | 0.34 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 86.09 | 87.78 |
Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, the development of new mines, the advancement of its exploration properties, and, targeting other consolidation opportunities with a focus on Africa.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.